Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

11.13 +0.62 (+5.90%)

Streaming Delayed Price Updated: 10:13 AM EDT, May 15, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	11,814
Open	11.09
Bid (Size)	10.54 (200)
Ask (Size)	11.30 (100)
Prev. Close	10.51
Today's Range	10.81 - 11.49
52wk Range	6.647 - 76.00
Shares Outstanding	34,422,063
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MiNK Therapeutics Q1 Earnings Call Highlights ↗

Today 10:12 EDT

MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute...

Via MarketBeat

MiNK Therapeutics (NASDAQ:INKT) Posts Narrower-Than-Expected Q1 Loss, Advances iNKT Therapy Into Pivotal Testing ↗

Today 8:20 EDT

Via Chartmill

Performance

YTD	+0.1%	+0.1%
1 Month	-17.6%	-17.6%
3 Month	+0.8%	+0.8%
6 Month	-15.8%	-15.8%
1 Year	+48.4%	+48.4%

More News

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Today 7:30 EDT

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

May 14, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

May 12, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

May 08, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

April 03, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

April 02, 2026

From MiNK Therapeutics

Via GlobeNewswire

These stocks are gapping in today's session ↗

April 01, 2026

Via Chartmill

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

April 01, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

March 31, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

March 17, 2026

From MiNK Therapeutics

Via GlobeNewswire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 11, 2026

Via Chartmill

What's going on in today's pre-market session ↗

March 11, 2026

Via Chartmill

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

March 10, 2026

Via Chartmill

Why Did INKT Stock Surge 70% In Pre-Market Today? ↗

March 10, 2026

Via Stocktwits

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

March 10, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

February 03, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

January 08, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

November 20, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics (INKT) Earnings Call Transcript ↗

November 14, 2025

Via The Motley Fool

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

November 14, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics's Earnings Outlook ↗

November 13, 2025

Via Benzinga

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

November 07, 2025

From MiNK Therapeutics

Via GlobeNewswire

Earnings Scheduled For November 14, 2025 ↗

November 14, 2025

Via Benzinga

Frequently Asked Questions

Is MiNK Therapeutics, Inc. - Common Stock publicly traded?

Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?

MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?

The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market

What is the current price of MiNK Therapeutics, Inc. - Common Stock?

The current price of MiNK Therapeutics, Inc. - Common Stock is 11.13

When was MiNK Therapeutics, Inc. - Common Stock last traded?

The last trade of MiNK Therapeutics, Inc. - Common Stock was at 05/15/26 10:13 AM ET

What is the market capitalization of MiNK Therapeutics, Inc. - Common Stock?

The market capitalization of MiNK Therapeutics, Inc. - Common Stock is 383.12M

How many shares of MiNK Therapeutics, Inc. - Common Stock are outstanding?

MiNK Therapeutics, Inc. - Common Stock has 383M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.